Orphan Drug Status for NanoViricides One Step Closer to Priority Review Voucher
Unless you're new here, you know about priority review vouchers (PRV). Designed by Duke University economists as a means of encouraging the development of drugs for unaddressed tropical diseases, PRVs were made law in 2007. Essentially, they are transferable go-to-the-front-of-the-regulatory-line “chits” awarded to companies that develop approved drugs for these orphan diseases. Estimates of the financial value of these chits range from $200 million to well over a half billion.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.